The tumor organoid efficacy evaluation platform has proven to be an invaluable tool for assessing the anticancer potential of small molecules. Using CRC organoids to validate human POC based on existing 2D experimental data, we observed that the drug demonstrated superior anticancer effects compared to conventional therapies. What stood out the most was the platform’s ability to accurately evaluate patient-specific drug responses using patient-derived tissues. Additionally, it simplified the process by reducing the complexities of approvals from collaborative institutions or IRBs, allowing for faster, independent research progress. The platform also facilitated patent acquisition based on the research findings. We are highly satisfied with the results and would strongly recommend utilizing this platform.